Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell L
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
| AbbVie (NYSE: ABBV) | Delayed: 276.47 +4.05 (1.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $272.42 | 52 Week High | $68.12 | |||
| Open | $271.53 | 52 Week Low | $50.71 | |||
| Day High | $277.60 | P/E | 59.97 | |||
| Day Low | $270.38 | EPS | $4.61 | |||
| Volume | 4,297,899 | |||||
